Gratze G, Fortin J, Labugger R, Binder A, Kotanko P, Timmermann B, Luft F C, Hoehe M R, Skrabal F
Department of Internal Medicine, Krankenhaus der Barmherzigen Brüder, Teaching Hospital of the Karl Franzens University Graz (Austria).
Hypertension. 1999 Jun;33(6):1425-30. doi: 10.1161/01.hyp.33.6.1425.
Recent evidence suggests that the prodownregulatory Gly16 allele of the beta-2 adrenergic receptor (beta-2 AR) is associated with essential hypertension in African Caribbeans. To further investigate the effect of the glycine (Gly)16 and arginine (Arg)16 beta-2 AR variants on hemodynamics, we investigated the agonist-mediated in vivo vasodilation in normotensive Austrian Caucasians and analyzed the results with respect to the Gly16/Arg16 polymorphism. Fifty-seven normotensive men, 20 to 32 years of age with body mass index of 18.7 to 29.9 kg/m2, were genotyped for the Arg16/Gly16 beta-2 AR alleles. All 15 Gly16/Gly16 subjects, all 12 Arg16/Arg/16 subjects, and 27 of 30 heterozygous subjects underwent hemodynamic measurements while supine after an overnight fast. The observers were unaware of the subjects' genotypes. The subjects received a graded infusion of the selective beta-2 AR agonist salbutamol (0.07, 0.14, and 0.21 microgram/kg per minute, respectively), each dose over 8 minutes. Stroke volume and blood pressure were determined continuously by means of impedance cardiography and oscillometry, respectively. The last 4 minutes of each infusion were evaluated statistically. Basal mean blood pressure was higher in the Gly16/Gly16 subjects compared with Arg16/Arg16 subjects (mean+/-SD: 81.6+/-6.14 versus 75.2+/-4.93 mm Hg, P<0.01). Homozygous Gly16 subjects showed a significantly decreased vasodilation during the first dose of salbutamol infusion compared with Arg16/Arg16 subjects (Deltatotal peripheral resistance index -17.9+/-14.4 versus -30. 6+/-8.3%, P<0.01) despite increased sympathetic counterregulation in the Arg16/Arg16 group (Deltaheart rate +16.9+/-7.0% versus +8.6+/-7. 0%, P<0.01; Deltacardiac index +39.5+/-18.5% versus 21.4+/-18.8%, P<0.05). Our results provide additional evidence that the Gly16/Arg16 alleles of the beta-2 AR are intimately related to blood pressure regulation and deserve further studies in the pathogenesis of essential hypertension.
近期证据表明,β-2肾上腺素能受体(β-2AR)的促下调型甘氨酸(Gly)16等位基因与非洲加勒比人中的原发性高血压相关。为了进一步研究甘氨酸(Gly)16和精氨酸(Arg)16β-2AR变体对血流动力学的影响,我们研究了正常血压的奥地利高加索人激动剂介导的体内血管舒张情况,并根据Gly16/Arg16多态性分析了结果。对57名年龄在20至32岁、体重指数为18.7至29.9kg/m2的正常血压男性进行了Arg16/Gly16β-2AR等位基因的基因分型。所有15名Gly16/Gly16受试者、所有12名Arg16/Arg16受试者以及30名杂合子受试者中的27名在禁食过夜后仰卧位时进行了血流动力学测量。观察者不知道受试者的基因型。受试者接受了选择性β-2AR激动剂沙丁胺醇的分级输注(分别为每分钟0.07、0.14和0.21μg/kg),每个剂量持续8分钟。分别通过阻抗心动图和示波法连续测定每搏输出量和血压。对每次输注的最后4分钟进行统计学评估。与Arg16/Arg16受试者相比,Gly16/Gly16受试者的基础平均血压更高(平均值±标准差:81.6±6.14对75.2±4.93mmHg,P<0.01)。与Arg16/Arg16受试者相比,纯合子Gly16受试者在首次输注沙丁胺醇期间血管舒张明显降低(总外周阻力指数变化-17.9±14.4对-30.6±8.3%,P<0.01),尽管Arg16/Arg16组的交感神经代偿性调节增加(心率变化+16.9±7.0%对+8.6±7.0%,P<0.01;心指数变化+39.5±18.5%对21.4±18.8%,P<0.05)。我们的结果提供了额外的证据,表明β-2AR的Gly16/Arg16等位基因与血压调节密切相关,在原发性高血压的发病机制中值得进一步研究。